Meeting
2022 ASCO Annual Meeting
Frontline treatment of follicular lymphoma with atezolizumab and obinutuzumab, with and without radiotherapy (The FLUORO study).
Authors
Eliza Anne Hawkes
Austin Health, Heidelberg, Australia
Eliza Anne Hawkes , Kate Manos , Richard Khor , Genevieve Douglas , Sze Ting Lee , Denise Lee , Belinda Campbell , Anneke Grobler , Michael Gilbertson , Jodie Palmer , Geoff Chong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04962126
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7587)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7587
Abstract #
TPS7587
Poster Bd #
235a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.
First Author: Miguel Angel A. Canales Albendea
Poster
2020 ASCO Virtual Scientific Program
Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.
First Author: William Townsend
Poster
2022 ASCO Annual Meeting
Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment.
First Author: Sarah Kim
Poster
2020 ASCO Virtual Scientific Program
First-line immunochemotherapy for follicular lymphoma in the GALLIUM study: Prognostic value of PET-CT status after long-term follow-up.
First Author: Tina Nielsen